Therapeutic Response

BRCA2 pathogenic variants status confers therapeutic sensitivity to Niraparib in patients with Peritoneal Serous Carcinoma.

Statements

Source and description

Zejula (niraparib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to niraparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Niraparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for niraparib.